Araceli Biosciences Raises $11.2 Million to Ramp up Drug Discovery with AI-powered analysis 

In the high-stakes world of biotech, speed can mean the difference between a missed breakthrough and a life-saving drug. While artificial intelligence has changed areas like genomics and robotics have accelerated lab processes, one critical piece of the drug discovery pipeline has remained painfully outdated that is its high-content imaging.

Despite advances elsewhere, researchers still spend hours or even days waiting for cellular imaging data to be processed and analyzed.

That’s the problem Araceli Biosciences is here to solve. The Portland-based biotech startup is on a mission to blow up the industry’s biggest bottleneck, and it's doing it with a next-generation platform that fuses ultra-fast imaging with real-time AI-powered analysis. With $11.2 million in fresh funding under its belt including $7.2 million in new equity investment and $4 million in converted SAFEs Araceli is gearing up to scale production, expand commercial reach, and continue redefining what speed means in scientific research.

The main reason for Araceli’s rising is Endeavor®, the company’s flagship high-content imaging system that captures cellular data up to 40 times faster than traditional solutions. But capturing images is only half the story. Paired with its proprietary AI analysis software, Clairvoyance, Endeavor doesn’t just collect data it interprets it in real time, slashing wait times, reducing experimental errors, and accelerating the pace of drug development. For researchers and pharmaceutical companies racing to understand how potential therapies interact with cells, this combination is a game-changer.